source
- FDA clears Click Therapeutics' Motivista, first digital therapeutic for negative schizophrenia symptomsClick Therapeutics received FDA 510(k) clearance for its digital therapeutic, Motivista (formerly CT-155), marking the first authorized treatment targeting negative symptoms of schizophrenia in the…
- California distributes over 120,000 low-cost insulin glargine packs as Novo Nordisk CEO warns investors on obesity drug differentiationCalifornia's state health program has been distributing a low-cost insulin glargine product, more than 120,000 five-pen packs since its launch seven months ago. Each pack is priced at $55, which i…